BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
MDM2
,
T cell differentiation
,
Diabetes mellitus
,
Pancreas
,
Autoimmunity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
protein subunits
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Protein subunit vaccines: Promising frontiers against COVID-19.
Understanding of protomers/deprotomers by combining mass spectrometry and computation.
Protomers of the green and cyan fluorescent protein chromophores investigated using action spectrosc…
Advances in protein subunit vaccines against tuberculosis.
Evaluate the potential use of TonB-dependent receptor protein as a subunit vaccine against Aeromonas…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years o…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ